Text Size

Non Alcoholic Fatty Liver Disease Influence of Statin Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2006 by Shaare Zedek Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Shaare Zedek Medical Center
ClinicalTrials.gov Identifier:
NCT00375349
First received: September 11, 2006
Last updated: NA
Last verified: August 2006
History: No changes posted
  Purpose

Aim:

  1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department.
  2. To assess the effect of statins on the prevalence of fatty liver by a cross sectional survey of patients hospitalized with chest pain.

Condition Intervention
Non-Alcoholic Fatty Liver Disease (NAFLD)
 Procedure: Ultrasound to demonstrate existence of fatty liver

Study Type: Observational
Study Design: Additional Descriptors: Convenience Sample
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Shaare Zedek Medical Center:

Study Start Date: September 2006
Estimated Study Completion Date: September 2009
Detailed Description:

Consecutive patients hospitalized with chest pain will be recruited at the cardiology department. Patients with an inflammatory condition, recent infection or history of alcoholism will be excluded. After signing an informed consent each patient will undergo an ultrasound examination for diagnosis of fatty liver. Information regarding BMI, hypertension and use of medications will be collected on each patient. Blood samples for fasting glucose, hemoglobin A1C, lipid profile, ESR, and CRP and liver function tests will be collected from each participant. Prevalence of fatty liver in patients who have been taking statins for 6 months or more statins will be compared to patients who have been taking statins for a lesser period and to those who do have not taken statins using a multivariate regression analysis.

Serum samples will be frozen and kept for future ongoing research.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cardiology patient
  • Age above 18

Exclusion Criteria:

  • Age below 18
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375349

Contacts
Contact: Michal Mates, MD 0544727635 Mates@013.net
Contact: Ornit Cohen Biton, MA 0507867234 bionet@017.net.il

Locations
Israel
Shaare Zedek Medical Center Not yet recruiting
Jerusalem, Israel, 91031
Contact: Michal Mates, MD     0544727635     Mates@013.net    
Principal Investigator: Michal Mates, MD            
Sub-Investigator: David Meerkin, MD            
Sponsors and Collaborators
Shaare Zedek Medical Center
Investigators
Principal Investigator: Michal Mates, MD Shaare Zedek Medical Center
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00375349     History of Changes
Other Study ID Numbers: 20173CTIL
Study First Received: September 11, 2006
Last Updated: September 11, 2006
Health Authority: Israel: Ethics Commission

Keywords provided by Shaare Zedek Medical Center:
fatty liver
statin
non-alcoholic

Additional relevant MeSH terms:
Fatty Liver
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on May 19, 2013